Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will take part in a fireside chat at 10:10 a.m. Central Time. A live audio webcast and an archived edition will be available via AbbVie's investor site.
AbbVie (NYSE: ABBV) will invest $380 million to build two new active pharmaceutical ingredient (API) facilities at its North Chicago campus, supporting next-generation neuroscience and obesity medicines. Construction starts spring 2026 and both facilities are expected to be fully operational in 2029.
The project will add advanced manufacturing and AI integration and is expected to create 300 jobs in engineering, science and operations, and is part of AbbVie's broader $100 billion U.S. R&D and capital commitment over the next decade.
AbbVie (NYSE: ABBV) announced FDA approval of the combination of VENCLEXTA (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL) on Feb 20, 2026.
The approval, supported by data from the Phase 3 AMPLIFY trial, establishes the first all-oral, fixed-duration regimen in the first-line CLL setting and offers a time-limited treatment option for patients and providers.
AbbVie (NYSE: ABBV) declared a quarterly cash dividend of $1.73 per share, payable May 15, 2026, to holders of record at the close of business on April 15, 2026.
Since 2013 AbbVie has increased its dividend by more than 330% and remains a member of the S&P Dividend Aristocrats Index.
AbbVie (NYSE:ABBV) reported full-year 2025 net revenues of $61.160 billion (+8.6% reported, +8.5% operational) and full-year GAAP diluted EPS of $2.36 (adjusted diluted EPS $10.00), which include an unfavorable $2.76 per-share impact from acquired IPR&D and milestones. Fourth-quarter revenues were $16.618 billion (+10.0% reported) with adjusted diluted EPS of $2.71 and GAAP EPS of $1.02. AbbVie provided 2026 adjusted diluted EPS guidance of $14.37–$14.57, excluding any acquired IPR&D and milestones impact.
Key portfolio highlights: Skyrizi $17.562B, Rinvoq $8.304B, Humira $4.540B; 2025 saw multiple regulatory submissions and an FDA approval for Epkinly in follicular lymphoma.
Allergan Aesthetics (NYSE: ABBV) launched the Faces of Natrelle® Testimonial Program on Feb 3, 2026, inviting U.S. women who had Natrelle® breast augmentation or reconstruction at age 22+ to submit photos, videos, and testimonials for possible publication.
Augmentation participants who are Allē members may receive five $100 Allē gift cards if selected and approved; reconstruction patients are encouraged to share but are not eligible for compensation. Important safety information and a Boxed Warning for breast implants are reiterated, including BIA-ALCL risk and recommended imaging timelines.
AbbVie (NYSE: ABBV) submitted applications to the FDA and EMA for upadacitinib (RINVOQ®) 15 mg once daily to treat adults and adolescents with non-segmental vitiligo. The filings are supported by Phase 3 Viti-Up results showing co-primary endpoints: T-VASI 50 and F-VASI 75 at week 48.
If approved, upadacitinib would be the first systemic therapy for vitiligo, addressing a high unmet need in a disease with substantial psychosocial burden and unpredictable progression.
AbbVie (NYSE: ABBV) launched Love in Mind™ on January 29, 2026, an educational initiative about the emotional impact of migraine on dating and romantic relationships. A Harris Poll of 606 adults found 89% struggle to be present, 51% canceled dates (avg. 8 times/year), and 78% push past pain to be intimate. Country artist Jessie James Decker shares her personal experience; relationship guidance is offered by Nedra Glover Tawwab. Resources and full survey findings are available at LoveInMind.com.
Allergan Aesthetics (NYSE: ABBV) will present nine e-posters and host symposia at IMCAS World Congress, Jan 29–31, 2026, in Paris showcasing facial injectable data across TrenibotulinumtoxinE, onabotulinumtoxinA (BOTOX Cosmetic), hyaluronic acid fillers, and a biostimulatory hybrid filler.
Pooled Phase 3 TrenibotulinumtoxinE results report rapid onset and short-duration effects; two Phase 4 onabotulinumtoxinA studies show long-term use benefits and patient satisfaction with natural outcomes. Allergan will highlight multimodal AA Signature™ approaches and live injection educational sessions.
AbbVie (NYSE: ABBV) reported topline Phase 3 EPCORE DLBCL-1 results for epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) on Jan 16, 2026. The trial enrolled 483 patients (73% with ≥2 prior lines) and showed improved progression-free survival (PFS) with HR 0.74 (95% CI 0.60–0.92). Improvements were also seen in complete response rate, duration of response, and time to next treatment. The study did not show a statistically significant overall survival benefit (OS HR 0.96; 95% CI 0.77–1.20). Safety was described as consistent with known epcoritamab profile. AbbVie and Genmab plan regulatory discussions and future data presentation.